-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2478 miRNA-144/451 Regulates Cell Surface TfR1 Expression in Normal and β-Thalassemic Erythroblasts

Program: Oral and Poster Abstracts
Session: 112. Thalassemia and Globin Gene Regulation: Poster II
Hematology Disease Topics & Pathways:
Research, Translational Research, Thalassemia, Hemoglobinopathies, Hematopoiesis, Diseases, Biological Processes, Molecular biology
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Georgios E. Christakopoulos, MD1, Alfonso G. Fernandez, PhD2*, Yu Yao, MD3*, Rahul Telange, MSc, BS4*, Dudley W. Michael5*, Tomas Ganz, MD, PhD6, Elizabeta Nemeth, PhD6 and Mitchell J Weiss, MD, PhD3

1Department of Hematology, St Jude Children's Research Hospital, Memphis, TN
2Dept. of Hematology, St Jude Children's Research Hospital, Memphis, TN
3Department of Hematology, St. Jude Childrens Research Hospital, Memphis, TN
4Dept. of Hematology, St. Jude Children's Research Hospital, Memphis, TN
5Hematology, St Jude Children's Research Hospital, MEMPHIS, TN
6Center for Iron Disorders, University of California, Los Angeles, Los Angeles, CA

β-thalassemia is a common inherited blood disorder caused by mutations in the β-globin gene (HBB) leading to a reduction of the corresponding protein. Consequently, excess free α-globin forms toxic intracellular inclusions causing hemolysis of circulating erythrocytes, maturation arrest and apoptosis of erythroid precursors (ineffective erythropoiesis). We showed recently that loss of the bi-cistronic erythroid microRNA locus miR-144/451 improves IE and hemolysis in the Hbbth3/+ mouse model for β-thalassemia through several potential mechanisms (PMID: 37339583). Loss of miR-451 caused de-repression of the LKB1 cofactor Cab39 leading to activation of AMPK, suppression of mTORC1 and enhanced ULK1-mediated autophagy of free α-globin. We also showed that miR-144/451−/− β-thalassemic erythroblasts exhibited 57% reduction in non-heme iron, activation of the eIF2α kinase heme-regulated inhibitor (HRI) and up to 45% reduction in cell surface expression of TfR1/CD71, the major iron importer into the cell. Thus, miR-144/451−/− may ameliorate β-thalassemia in part by inducing iron restriction (PMID 30401707). Hence, we sought to understand how miR-144/451 regulates cell surface TfR1/CD71 expression in normal and β-thalassemic erythroblasts.

In developmental stage-matched (EryB, CD71high/FSClow) splenic erythroblasts from WT (Hbb+/+) or β-thalassemia (HbbTh3/+) mice, germline loss of miR-144/451 caused 16 ± 4 % (p<0.05) or 55± 9 % (p<0.001) reductions in cell surface TfR1/CD71, respectively, as measured by immuno-flow cytometry. Western blot (WB) analysis of Hbb+/+ or HbbTh3/+ Ter119+ splenic erythroblasts showed 32 ± 14 % (p<0.05) or 67 ± 23% (p<0.01) reductions of TfR1 protein, respectively. RT-PCR analysis of the same cells showed no significant differences in the levels of mature or nascent (intron-containing) TfR1 mRNAs upon loss of miR-144/451. These findings suggest that miR-144/451 regulates the expression of TfR1 translationally or post-translationally. Compared to splenic erythroblasts, loss of miR-144/451 had a smaller effect on TfR1/CD71 expression in bone marrow erythroblasts. These findings suggest that that miR-144/451 regulates TfR1 expression preferentially during stress erythropoiesis, which occurs in the spleen of mice.

To investigate whether TfR1 expression is regulated by MIR-144/451 during human erythropoiesis, we used Cas9 to disrupt the miRNA locus in healthy donor (HBB+/+), peripheral blood-mobilized CD34+ hematopoietic stem and progenitor cells (HSPCs) as well as in β-thalassemia (HBB-/-) bone marrow derived CD34+ HSPCs followed by in vitro erythroid differentiation. Immuno-flow cytometry showed that MIR-144/451 disruption in developmental stage-matched CD49d+/Band3+ or CD49d-/Band3+ human HBB+/+ erythroblasts caused 61 ± 7 % (p<0.001) or 41 ± 13 % (p<0.01) reductions in cell surface TfR1/CD71, respectively. Similar findings were observed in HBB-/- erythroblasts. Thus, the regulation of TfR1 expression by miR-144/451 during erythropoiesis is conserved between mice and humans. We are currently investigating further the mechanisms by which miR-144 and/or miR-451 promote TfR1 expression at the cell surface, including the identification of relevant microRNA target mRNAs.

Disclosures: Weiss: Cellarity Inc., Novartis, and Forma Therapeutics: Membership on an entity's Board of Directors or advisory committees.

*signifies non-member of ASH